According to EffRx Pharmaceuticals, Swissmedic has approved Bronchitol inhaled dry powder mannitol as an add-on to other medications for the treatment of cystic fibrosis in patients 6 years old and older. EffRx acquired Swiss rights to Bronchitol from Pharmaxis in 2019. The company said that it expects to launch the DPI in Switzerland in the second half of 2022.
Bronchitol was approved in the EU for the treatment of CF in adults in 2012. Chiesi distributes the DPI in a number of European countries, including Italy, Ireland, and Germany, as well as the UK. In the US, Chiesi announced that it had received FDA approval to market Bronchitol for the treatment of CF in adult patients in November 2020 and launched the DPI in March 2021. The inhaler is also currently marketed in Russia and Australia.
EffRx Senior Director, Medical Affairs, Lorraine Zakin said, “We’re excited to have achieved this important milestone and that patients living with cystic fibrosis will be able to benefit from this treatment in Switzerland. Bronchitol offers a portable and discreet option for CF management, with no routine cleaning or maintenance of the inhaler device required.”
Read the EffRx Pharmaceuticals press release.
